TOULON, France--(BUSINESS WIRE)--June 26, 2006--The Immune Response Corporation (OTCBB:IMNR - News) announced today that preliminary Phase II study results of its second-generation HIV immunotherapy, IR103, demonstrated a positive safety profile and enhanced immunomodulatory effects over REMUNE®, the Company's first-generation immunotherapy. IR103 is a co-formulation of REMUNE® and a novel synthetic Toll-like receptor (TLR-9) agonist adjuvant, Amplivax(TM). The results were presented at the International Symposium on HIV & Emerging Infectious Diseases (ISHEID) in Toulon, France.
